Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Express Scripts
McKinsey
Dow

Last Updated: August 19, 2022

Investigational Drug Information for Tirasemtiv


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Tirasemtiv?

Tirasemtiv is an investigational drug.

There have been 8 clinical trials for Tirasemtiv. The most recent clinical trial was a Phase 3 trial, which was initiated on October 17th 2016.

The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Cytokinetics, National Institute of Neurological Disorders and Stroke (NINDS), and [disabled in preview].

There are fourteen US patents protecting this investigational drug and one hundred and twenty-three international patents.

Recent Clinical Trials for Tirasemtiv
TitleSponsorPhase
A Study for Patients Who Completed VITALITY-ALS (CY 4031)CytokineticsPhase 3
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearCytokineticsPhase 3
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)CytokineticsPhase 2

See all Tirasemtiv clinical trials

Clinical Trial Summary for Tirasemtiv

Top disease conditions for Tirasemtiv
Top clinical trial sponsors for Tirasemtiv

See all Tirasemtiv clinical trials

US Patents for Tirasemtiv

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tirasemtiv See Plans and Pricing Increase of protein synthesis ameliorates synaptopathy-related neurological disorders Academia Sinica (Taipei, TW) See Plans and Pricing
Tirasemtiv See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Tirasemtiv See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Express Scripts
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.